Corrigendum: TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS , STK11 and KEAP1 mutations.

MLA

Frille, Armin, et al. “Corrigendum: TP53 Co-Mutations in Advanced Lung Adenocarcinoma: Comparative Bioinformatic Analyses Suggest Ambivalent Character on Overall Survival alongside KRAS , STK11 and KEAP1 Mutations.” Frontiers in Oncology, vol. 14, Sept. 2024, p. 1473239. EBSCOhost, https://doi.org/10.3389/fonc.2024.1473239.

APA

Frille, A., Boeschen, M., Wirtz, H., Stiller, M., Bläker, H., & von Laffert, M. (2024). Corrigendum: TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS , STK11 and KEAP1 mutations. Frontiers in Oncology, 14, 1473239. https://doi.org/10.3389/fonc.2024.1473239

Chicago

Frille, Armin, Myriam Boeschen, Hubert Wirtz, Mathias Stiller, Hendrik Bläker, and Maximilian von Laffert. 2024. “Corrigendum: TP53 Co-Mutations in Advanced Lung Adenocarcinoma: Comparative Bioinformatic Analyses Suggest Ambivalent Character on Overall Survival alongside KRAS , STK11 and KEAP1 Mutations.” Frontiers in Oncology 14 (September): 1473239. doi:10.3389/fonc.2024.1473239.